Provided by Tiger Trade Technology Pte. Ltd.

crane

206.11
-0.2200-0.11%
Post-market: 206.110.00000.00%19:30 EDT
Volume:343.16K
Turnover:70.77M
Market Cap:11.87B
PE:35.97
High:210.77
Open:210.20
Low:205.18
Close:206.33
52wk High:230.50
52wk Low:159.58
Shares:57.60M
Float Shares:48.76M
Volume Ratio:0.76
T/O Rate:0.70%
Dividend:0.97
Dividend Rate:0.47%
EPS(TTM):5.73
EPS(LYR):6.26
ROE:16.52%
ROA:12.73%
PB:5.45
PE(LYR):32.95

Loading ...

Crane Holdings Q1 Adj. EPS $1.65 Beats $1.45 Estimate, Sales $696.400M Beat $672.739M Estimate

Benzinga Earnings
·
Apr 28

BRIEF-Crane Company Q1 Sales USD 696.4 Million Vs. IBES Estimate USD 672.7 Million

Reuters
·
Apr 28

Crane Company Q1 EPS USD 1.14

THOMSON REUTERS
·
Apr 28

Crane Company Q1 Adjusted EPS USD 1.65 VS. Ibes Estimate USD 1.45

THOMSON REUTERS
·
Apr 28

Crane Company Reports First Quarter 2026 Results and Raises Full Year EPS Guidance

THOMSON REUTERS
·
Apr 28

Crane options imply 6.3% move in share price post-earnings

TIPRANKS
·
Apr 28

Crane names Alex Alcala CEO as Max Mitchell becomes executive chairman

Reuters
·
Apr 27

Crane Company Announces Completion of CEO Succession

THOMSON REUTERS
·
Apr 27

Top News Today/Canada: Retail Sales Improve Ahead of Expected Squeeze

Dow Jones
·
Apr 25

Earning Preview: Crane Company revenue expected to increase by 22.77%, and institutional views are bullish

Earnings Agent
·
Apr 20

Crane (CR) Valuation Check As Shares Deliver Mixed Short And Long Term Returns

Simply Wall St.
·
Apr 19

Crane Is Maintained at Hold by Stifel

Dow Jones
·
Apr 14

Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC

prnewswire
·
Apr 13

Crane Company updates financial calendar for first-quarter earnings release and call

Reuters
·
Apr 07

Crane Company Announces Date for First Quarter 2026 Earnings Release and Teleconference

THOMSON REUTERS
·
Apr 07

Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 30

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

GlobeNewswire
·
Mar 30

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

Benzinga
·
Mar 26

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

GlobeNewswire
·
Mar 26

Do Macro Shocks Reveal Hidden Cyclicality In Crane (CR)’s Specialized Technology Story?

Simply Wall St.
·
Mar 25